



SWAMY VIVEKANANDHA COLLEGE OF PHARMACY

(Affiliated to the The Tamil Nadu Dr.MGR. Medical University, Chennai,
Approved by PCI, Accredited by NBA, New Delhi)
Elayampalayam, Tiruchengode-637 205, Namakkal (Dt), Tamil Nadu.



Department of Pharmacy Practice

Presents

ADR PULSE RADAR

(SPOT IT, STOP IT)

VMCH ADR ALERT: JULY 2026

'Pharmacovigilance - Passive Surveillance'

VMCH AMC CHAIRMAN : Dr. S. ARTHANAREESWARAN, M.D.,

VMCH AMC CO-ORDINATOR : Dr. R. SUBASHINI, M.Pharm., Ph.D.,

DEPUTY CO-ORDINATOR : Dr. K. JEYAPRAKASH, M.D.,

TECHNICAL ASSISTANCE : Dr. T. ANGELIN GRACE, Pharm.D.,

ADVISORY BOARD : Dr. K. KRUPANITHI, M.D.,

Dr. K. B. NIVETHANA KRUPANIDHI, M.S.,

Dr. G. MURUGANANTHAN, Principal - SVCP

PATRON : PROF. Dr. M. KARUNANITHI, B.PHARM., M.S., PH.D., D.LITT.,

Visit Our Website
svcop.ac.in




VMCH ADR SUMMARY

Total ADR : 28
Most Common : CARDIOLOGY
(82.1%)
Serious Cases : NIL

ADRs INVOLVED

Antidiabetic – 28.57%, Antihypertensive – 28.57%,
Antiplatelet – 10.71%, Anticoagulant – 7.14%, Laxative –
7.14%, Lipid-lowering drugs 3.57%, Antianginal drugs
3.57%, Antidepressants-3.57%, Corticosteroids 3.57%,
Antibiotics 3.57%.



IF ANY ADR, SCAN AND REPORT HERE



Email Id: vmchadr@gmail.com

FDA ANNOUNCEMENT

Bevacizumab-vikg (Lytenava) is the first FDA-approved ophthalmic formulation of bevacizumab developed by Outlook Therapeutics for neovascular (wet) age-related macular degeneration (nAMD). It is administered as an intravitreal injection.

Bevacizumab-vikg is a recombinant humanized monoclonal antibody that binds to VEGF, preventing its interaction with VEGFR-1 (Flt-1) and VEGFR-2 (KDR) on endothelial cells. This inhibits retinal neovascularization, vascular leakage, and endothelial cell proliferation, helping preserve vision.

REFERENCES

- https://outlooktherapeutics.com/pipeline/new-anti-vegf-for-ophthalmic_indications.
- <https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026>.

-G. Krupadevi , J. Christy Immaculate
PHARM D INTERN

FDA DRUG INFORMATION

TRUTAKNA


The U.S. Food and Drug Administration (FDA) has approved Trutakna (atacept-vymj) on July 7, 2026 as the first targeted therapy to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression. Trutakna is indicated to reduce proteinuria, an important marker of kidney damage, thereby helping to slow the progression of chronic kidney disease associated with IgAN. Trutakna is a recombinant fusion protein that inhibits the activity of B-cell Activating Factor (BAFF) and A Proliferation-Inducing Ligand (APRIL), two cytokines involved in B-cell maturation and antibody production. By blocking BAFF and APRIL, Trutakna reduces the production of pathogenic galactose-deficient IgA1 antibodies and immune complex formation, thereby decreasing glomerular inflammation and proteinuria.



Clinical studies demonstrated that Trutakna significantly reduced urine protein excretion (proteinuria) compared with placebo while maintaining an acceptable safety profile. Trutakna treats IgA nephropathy by targeting immune mechanisms, potentially slowing kidney function decline. Common adverse effects include infections, headache, nasopharyngitis, injection-site reactions, and urinary tract infections.

REFERENCES

1. U.S. Food and Drug Administration. FDA approves Trutakna (atacept-vymj) for primary immunoglobulin A nephropathy to reduce proteinuria in adults at risk for disease progression. Silver Spring (MD): U.S. Food and Drug Administration; 2026 Jul 7.
2. Vera Therapeutics. FDA approves Trutakna (atacept-vymj) for the treatment of adults with primary IgA nephropathy at risk of disease progression. Press Release; 2026 Jul 7.




FDA DRUG INFORMATION

Lipfendra (enlicitide)

The U.S. Food and Drug Administration (FDA) has approved Lipfendra (enlicitide) 20 mg tablets, the first oral PCSK9 inhibitor, as an adjunct to diet and exercise for reducing low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). Lipfendra offers the first non-injectable PCSK9-targeted therapy, providing a convenient once-daily oral option for patients who require additional LDL-C lowering despite existing lipid-lowering treatment.



It works by inhibiting the PCSK9 protein, increasing LDL receptor recycling in the liver and enhancing removal of LDL cholesterol from the bloodstream. Clinical trials demonstrated an LDL-C reduction of approximately 55-60% when added to standard therapy. The most commonly reported adverse effects include diarrhea, dizziness, and abdominal discomfort.



Lipfendra represents a significant advancement in lipid management and may improve adherence in patients who prefer oral medication over injectable PCSK9 inhibitors. Cardiovascular outcome trials are ongoing to determine its long-term benefits in reducing heart attack and stroke risk.

REFERENCES

1. U.S. Food and Drug Administration. FDA approves first oral PCSK9 inhibitor to lower LDL cholesterol in adults with high cholesterol. Silver Spring (MD): [U.S. Food and Drug Administration; 2026 Jul 16](#)
2. Reuters. Merck gets US FDA nod for first-in-class oral cholesterol drug. [Reuters; 2026 Jul 16](#)

NEUROFIBROMATOSIS

SHORT COMMUNICATION



Neurofibromatosis is a genetic disorder characterized by the development of multiple benign nerve sheath tumors, commonly affecting the skin and nervous system. It is mainly caused by mutations in the NF1 gene, leading to loss of tumor suppressor function.



Portrayed Picture

SUMMARY

This case highlights the importance of early diagnosis, genetic counseling, and multidisciplinary management in preventing complications and improving the quality of life in patients with neurofibromatosis.

CASE REPORT


A 20-year-old female with a family history of similar complaints presented with multiple painless skin nodules, café-au-lait spots, and axillary freckling since childhood. She also reported occasional headaches and visual disturbances. Clinical examination revealed multiple cutaneous neurofibromas and hyperpigmented macules. Ophthalmological evaluation confirmed the presence of Lisch nodules. Radiological investigations were performed to rule out associated complications such as optic glioma. The diagnosis of Neurofibromatosis Type 1 was made based on NIH diagnostic criteria. The patient was managed conservatively with regular monitoring, symptomatic treatment, and counseling regarding the genetic nature of the disease. Surgical intervention was considered for cosmetically disfiguring lesions. Pharmacist interventions included patient education, monitoring for drug-related adverse effects, and ensuring adherence to follow-up.

**-DHIVYA.B , DHIVYA.P
V- PHARM. D**



ADR CASE

ASPIRIN INDUCED HEMOPTYSIS IN PATIENT DIAGNOSED WITH CAD



PATIENT DETAILS



Age : 74 Year



Sex : Male



Drug : Tablet Aspirin



Dose : 75 mg



Route of Administration : PO, Oral



Starting Date : 20/08/2018



Withheld Date : 24/07/2026
(Aspirin was withheld due to hemoptysis)



Reaction Date : 24/07/2026



CAUSALITY ASSESSMENT

WHO UMC
(PROBABLE)




OUTCOME
RECOVERED



MANAGEMENT

ASPIRIN WAS WITHHELD.
PATIENT WAS TREATED
SUPPORTIVELY AND
MONITORED.
HEMOPTYSIS RESOLVED AND
PATIENT RECOVERED.



Aspirin (Acetylsalicylic Acid)



Used in CAD



Can cause bleeding
leading to hemoptysis





VIVEKANANDHA EDUCATIONAL INSTITUTIONS



"Vidhya Rathna"

Prof. Dr. M. KARUNANITHI, B.Pharm., M.S., Ph.D., D.Litt.,
Chairman & Secretary

TIRUCHENGODE CAMPUS

- ★ SWAMY VIVEKANANDHA MEDICAL COLLEGE HOSPITAL AND RESEARCH INSTITUTE
- ★ VIVEKANANDHA DENTAL COLLEGE FOR WOMEN
- ★ SWAMY VIVEKANANDHA COLLEGE OF PHARMACY
- ★ VIVEKANANDHA COLLEGE OF NURSING
- ★ SWAMY VIVEKANANDHA PHYSIOTHERAPY COLLEGE
- ★ VIVEKANANDHA ALLIED HEALTH SCIENCE COLLEGE
- ★ KRISHNA INSTITUTE OF OPTOMETRY & RESEARCH
- ★ VIVEKANANDHA COLLEGE OF ENGINEERING FOR WOMEN (AUTONOMOUS)
- ★ VIVEKANANDHA COLLEGE OF TECHNOLOGY FOR WOMEN
- ★ VIVEKANANDHA INSTITUTE OF INFORMATION AND MANAGEMENT STUDIES
- ★ VIVEKANANDHA COLLEGE OF ARTS AND SCIENCES FOR WOMEN (AUTONOMOUS)
- ★ VIVEKANANDHA COLLEGE FOR WOMEN
- ★ VIVEKANANDHA COLLEGE OF EDUCATION FOR WOMEN
- ★ VIVEKANANDHA VIDHYA BHAVAN MATRIC HIGHER SECONDARY SCHOOL
- ★ VIDYAA VIKAS MATRIC HIGHER SECONDARY SCHOOL (MOREPALAYAM)
- ★ VIVEKANANDHA MEDICAL CARE HOSPITAL (VMCH)

SANKAGIRI CAMPUS

- ★ SWAMY VIVEKANANDHA NATUROPATHY AND YOGA MEDICAL COLLEGE
- ★ VIVEKANANDHA PHARMACY COLLEGE
- ★ VIVEKANANDHA NURSING COLLEGE FOR WOMEN
- ★ VIVEKANANDHA ARTS AND SCIENCE COLLEGE
- ★ RABINDHARANATH TAGORE COLLEGE OF EDUCATION FOR WOMEN
- ★ VISWABHARATHI COLLEGE OF EDUCATION FOR WOMEN



Elayampalayam - 637 205, Tiruchengode Tk., Namakkal Dt., Tamil Nadu.

Mobile : 94437 34670, 99655 34670.

Veerachipalayam - 637 303, Sankari Tk., Salem Dt., Tamil Nadu.

Mobile : 99425 34564, 97888 54417.

website : www.vivekanandha.ac.in